|
|
|
Scientific Programme
|
|
Pre-Conference Workshop, 7 October 2008 (Tuesday)
|
|
Main
Programme, Day 1, 8 October 2008 (Wednesday)
|
|
Main
Programme, Day 2, 9 October 2008 (Thursday)
|
|
Main
Programme, Day 3, 10 October 2008 (Friday)
|
|
Main
Programme, Day 4, 11 October 2008 (Saturday)
|
|
Novartis Lunch Symposium, 8 October 2008 (Wednesday)
|
|
Novartis
Dinner Symposium, 8 October 2008 (Wednesday)
|
|
Osato Lunch Symposium, 9 October 2008 (Thursday)
|
|
|
|
Pre-Conference Workshop, 7 October 2008 (Tuesday)
|
|
KK Women's and Children's Hospital
|
|
The Auditorium
|
Workshop 1 ( 0900 - 1200 )
Magnetic Resonance T2* Assessment of Iron Overload
|
Workshop 2 ( 1400 - 1700 )
Diagnosis of Thalassaemia - Laboratory Methods, Molecular Basis and Screening Strategy
|
|
|
TOP>
|
|
Main Programme, Day 1, 8 October 2008 (Wednesday)
|
|
Suntec Singapore International Convention & Exhibition Centre
|
|
Ballroom 1
|
|
Opening Ceremony ( 0815 - 0915 )
|
Plenary 1 ( 0915 - 1000 )
Thalassaemia As a Global Health Problem,
Sir David
WEATHERALL, United Kingdom
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1000 - 1045 )
|
|
Room 1
|
Room 2
|
Room 3
|
|
11th International Conference on Thalassaemia &
Haemoglobinopathies
|
13th International TIF Conference for
Thalassaemia Patients & Parents
|
Free Paper Sessions
|
Symposium 1 ( 1045 - 1215 )
Molecular Therapeutics and Alternative Therapies for Thalassaemia
Chairpersons: Prof Eliezer RACHMILEWITZ, Israel /
Dr Michael ANTONIOU, United Kingdom
|
- Gene Therapy - Is It A Reality?
Dr Michael ANTONIOU, United Kingdom
- Molecular Therapies in
Beta-Thalassaemia
Prof THEIN Swee Lay,
United Kingdom
- Oxidative Stress in Thalassaemia and
Haemoglobinopathies: Mechanism and Treatment
Prof Eliezer RACHMILEWITZ, Israel
|
|
Session 1 (1045 - 1215 )
Chairpersons: Prof Alan COHEN,United States of Amercia / Mrs Aggie MICHAEL, Singapore
|
|
What is Thalassaemia?
|
-
Background - How / Why Do We Get Thal? How
Does It Become Major? When Does Treatment Start?
Dr Paul TELFER, United Kingdom
-
Prevention, Screening & Ethics
Dr Mary PETROU, United Kingdom
-
Transplantations
Dr Phil DARBYSHIRE, United Kingdom
|
|
Blood Transfusions
|
- Why Do Patients Need Blood Transfusions, What
Happens During Transfusions? What Do We Do When There's A Reaction?
Dr Diana TEO, Singapore
|
|
Q & A
|
|
Free Papers 1
( 1045 - 1215 )
|
Novartis
Lunch Symposium
(For Medical Professionals only)
( 1215 - 1345 )
|
Lunch Break
( 1215 - 1330 )
|
Lunch Break
( 1215 - 1330 )
|
Symposium 2 ( 1345 - 1515 )
Epidemiology
Chairpersons: Sir David WEATHERALL,
United Kingdom / Dr Vip VIPRAKASIT, Thailand
|
- Why Are The Haemoglobin Disorders So Common?
Sir David WEATHERALL, United Kingdom
- Global Distribution and Heterogeneity of the Alpha
Thalassaemias
Dr Vip VIPRAKASIT, Thailand
- Epidemiology of the Beta Thalassaemias
Dr Roshan COLAH, India
|
|
Session 2 ( 1330 - 1500 )
Chairpersons: Dr TAN Ru-San, Singapore /
Ms Gargi PAHUJA, United States of America
|
Blood Donation
|
- How to Encourage Voluntary Blood Donation?
Myths & Beliefs of Blood Giving
Speaker to be confirmed
- Blood Transfusion and What It Means to
Thalassaemics?
Mr George CONSTANTINOU, United Kingdom
|
Heart & Its Problems
|
- Cardiac Problems & Solutions
Dr Malcolm WALKER, United Kingdom
- Cardiac Problems & How Do We Deal with It in Asia
(Before & After MRI T2*)?
Dr DAN Giap Liang, Malaysia
|
| Q & A
|
|
Free Papers 2
( 1330 - 1500 )
|
|
Tea break at Exhibition Area (Concourse, Level
3)
( 1515 - 1545 )
|
Tea break at Exhibition Area
(Concourse, Level 3)
(
1500 - 1535 )
|
|
Symposium 3 ( 1545 - 1725 )
Prevention
Chairpersons: Dr Mary PETROU, United Kingdom /
Dr THONG Meow Keong, Malaysia
|
- Screening and Ethics of Prevention
Dr Mary PETROU, United Kingdom
- Thalassaemia Screening
Programmes: The
Malaysian Experience
Dr THONG Meow Keong, Malaysia
- Non-Invasive Prenatal Diagnosis
Prof Rossa CHIU, Hong Kong SAR
- Pre-implantation Genetic Diagnosis
Prof Anver KULIEV, United States of America
- Pre-implantation Genetic Diagnosis:
The Singapore Experience
A/Prof Samuel CHONG, Singapore
|
|
Session 3 ( 1530 ?1700 )
Chairpersons: Dr Paul TELFER, United Kingdom /
Ms LEOW Siew Tin, Singapore
|
- Growth & Development - Puberty
Dr Nikos SKORDIS, Cyprus
- Endocrinology
Dr Vera OH, Singapore
- Bones, Osteoporosis
Dr Ersi Dimoula VOSKARIDOU, Greece
- Diet
Ms Christine ONG, Singapore
|
| Q & A
|
|
Free Papers 3
( 1530 - 1710 )
|
|
Novartis Dinner Symposium
(For Medical Professionals only)
( 1830 - 2100 )
|
|
|
|
|
TOP>
|
|
Main Programme, Day 2, 9 October 2008 (Thursday)
|
|
Suntec Singapore International Convention & Exhibition Centre
|
|
Room 1
|
Room 2
|
11th International Conference on
Thalassaemia & Haemoglobinopathies
|
13th International TIF Conference for Thalassaemia Patients & Parents
|
Plenary 2 ( 0800 - 0835 )
Survival Trends in Thalassaemia Major
Dr Caterina BORGNA-PIGNATTI, Italy
|
|
Symposium 4 ( 0835 -
1000 )
Infections in Thalassaemia
Chairperson: Dr TAN Ban Hock, Singapore / Dr KOH Pei Lin, Singapore
|
- Immune Status of Chronically Transfused Patients
Dr LI Chi Kong, Hong Kong SAR
- Overview of Infections in Thalassaemia
Prof Galia RAHAV, Israel
- Management of Asplenic Patients
Dr TAN Ban Hock, Singapore
|
|
Parents/Patients Interactive Session
( 0830 - 1000 )
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1000 - 1020 )
|
Symposium 5 ( 1020 - 1150 )
Cardiac Complications
Chairperson/s:Dr TAN Ru San, Singapore/
Dr Athanasios AESSOPOS, Greece
|
- The Heart in Transfusion Dependent Thalassaemia
Dr Athanasios AESSOPOS, Greece
- The Role of MRI T2*
Dr Dudley PENNELL, United Kingdom
- Treatment of Heart Failure in
Thalassaemia Major
Dr John WOOD, United States of Amercia
|
|
Parents/Patients Interactive Session
( 1020 - 1150 )
Lunch Break
( 1150 - 1305 )
|
|
Osato Lunch Symposium (By Invitation)
( 1150 - 1320 )
|
Lunch Break
( 1150 - 1305 )
|
|
Launch of TIF New Guidelines Book
(1320 - 1340)
Dr Androulla ELEFTHERIOU, Cyprus
|
|
Plenary 3 ( 1340 - 1420 )
New Insights in Iron Chelation
Prof Antonio PIGA, Italy
|
Symposium 6 ( 1420 - 1540 )
Iron Chelation 1
Chairpersons: Dr Dudley PENNELL, United Kingdom /
Prof John PORTER, United Kingdom
|
- Pathophysiology of Iron Overload
Dr Z Ioav CABANTCHIK, Israel
- Iron Overload: Consequences
Prof John PORTER, United Kingdom
- Iron Chelation: Overview and Monitoring
Prof Maria Domenica CAPPELLINI, Italy
- Iron Chelation: Impact on Survival
Dr Paul TELFER, United Kingdom
|
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1540 - 1610 )
|
Symposium 7
( 1610 - 1740 )
Iron Chelation 2
Chairpersons: Prof Aurelio MAGGIO, Italy / Prof Maria Domenica
CAPPELLINI, Italy
|
- Future Developments in Oral Iron Chelators
Dr Des R RICHARDSON
- Is There an Optimal Strategy for Iron
Chelation?
Prof Renzo GALANELLO, Italy
- Management of the 'Difficult'Iron Overloaded Patient
Prof Aurelio MAGGIO, Italy
|
|
|
|
Conference Dinner (By Ticket
ONLY)
( 2000 -
2230 )
|
|
|
TOP>
|
|
Main Programme, Day 3, 10 October 2008 (Friday)
|
|
Suntec Singapore International Convention & Exhibition Centre
|
|
Room 1
|
Room 2
|
Room 3
|
|
11th International Conference on Thalassaemia &
Haemoglobinopathies
|
13th International TIF Conference for Thalassaemia Patients & Parents
|
|
Plenary 4 ( 0800 - 0835 )
Fertility and Pregnancy in Thalassaemia Major
Dr Susan M TUCK, United Kingdom
|
Session 4 ( 0800 - 0930 )
Chairpersons: Prof Antonio PIGA, Italy/ Mr George CONSTANTINOU,
United Kingdom
|
- HbE & Thalassaemia
Intermediate
Dr Vip VIPRAKASIT, Thailand
|
Chelation
|
- Different Types of
Chelators
Prof Alan COHEN, United States of America
- Iron Chelation Treatment
Under Economic Restrictions
Dr Suthat FUCHAROEN, Thailand
- Iron Overload and
Consequences
Dr GOH Ai Sim, Malaysia
|
| Q & A
|
|
Symposium 8 ( 0835 - 1020 )
Endocrine Complications
Chairperson/s: Dr Ratna CHATTERJEE, United Kingdom /
Dr Rekha BAJORIA, United Kingdom
|
- New Perspectives on Hormone Replacement Therapy in
Thalassaemia
Dr Ratna CHATTERJEE, United Kingdom
- Growth and Thalassaemia
Dr Fabian YAP, Singapore
- Current Perspectives on Pregnancies in Thalassaemia Major
Dr Rekha BAJORIA, United Kingdom
- The Burden of Osteoporosis in Thalassaemia
Dr Ersi Dimoula VOSKARIDOU, Greece
- The Impact of Genotype on Endocrine Complications
Dr Nikos SKORDIS, Cyprus
|
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1020 - 1040 )
|
Symposium 9 (1040 - 1210)
Liver Disease in Thalassaemia
Chairpersons: Dr LEE Lai Heng, Singapore / Prof Ali TAHER, Lebanon
|
- Overview of Liver Disease in Thalassaemia
Dr James O'BEIRNE, United Kingdom
- Update on Management and Prevention of Hepatitis B
A/Prof CHOW Wan Cheng, Singapore
- Hepatitis C in Thalassaemia Patients
Dr Roland CHONG, Singapore
|
|
Session 5 ( 1000 - 1130 )
Chairpersons:
Tan Ee Shien, Singapore / Mr Michael MICHAEL, United Kingdom
|
Psychosocial Problems
|
- Patient's Perspectives
Ms Louisa Di PIETRO, Australia
- Parent's Perspectives
Mrs Nailya T GULIYEVA, Azerbaijian
|
Hospital & Doctor Relationships
|
- Doctors' Relationship and Responsibilities
Prof Amal EL-BESHLAWY, Egypt
- Hospitals Relationship and Responsibilities
To be confirm
|
| Q & A
|
|
|
Lunch Break
(
1210 - 1310)
|
Lunch Break
( 1130 - 1300)
|
|
Plenary 5 (1310 - 1345)
Emerging Infections in Blood Transfusions
Dr Roger Y DODD, United States of America
|
Session 6 ( 1300 - 1430 )
Chairpersons: Dr GOH Ai Sim, Malaysia/
Mr Riyad ELBARD, Canada
|
Symposium 10 ( 1345 - 1525 )
Blood Transfusion
Chairpersons: Dr Diana TEO, Singapore/
Prof Constantina POLITIS, Greece
|
- Blood Safety in the Asia Pacific Region
Dr Diana TEO, Singapore
- Haemovigilance and Transfusion Safety
Dr Peter FLANAGAN, New Zealand
- Advances in Blood Transfusion Therapy
Prof Alan COHEN, United States of America
- Red Blood Cell Pathogen Inactivation
Prof Constantina POLITIS, Greece
|
|
|
Liver & Its Problems
|
- How / Why Liver Has Its Problems? What are the Problems? How
to Detect (Signs and Symptoms)?
Dr LI Chi Kong, Hong Kong SAR, China
- Future Treatments for Liver Problems / Failure
Dr James O'BEIRNE, United Kingdom
|
Iron Measurement - MRI & Its Roles
|
- T2*
Dr TAN Ru-San, Singapore
- Ferriscan
Dr Farrukh SHAH, United Kingdom
|
|
Q & A
|
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1525
- 1545 )
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1430 - 1500 )
|
Symposium 11 (1545 - 1715)
Thalassaemia Intermedia / HbE
Chairpersons: Prof Eliezer RACHMILEWITZ, Israel /
Dr Anselm LEE, Singapore
|
- Thromboembolic Complications in Thalassaemia Intermedia
Prof Ali TAHER, Lebanon
- Cardiac Function and Abnormalities in Thalassaemia
Intermedia
Dr Athanasios AESSOPOS, Greece
- Haemoglobin E-b-Thalassaemia
Dr Suthat FUCHAROEN, Thailand
|
|
Session 7 (1500 - 1610)
Chairpersons: Dr Michael ANGASTINIOTIS, Cyprus /
Mrs Nailya T GULIYEVA, Azerbaijan
|
- Government Relationships & Responsibilities
Ms Dawn ADLER, United States of America
- Nurses' Relationships & Responsibilities
S/r Emma PRESCOTT, United Kingdom
- Nurses' Relationships & Responsibilities, The Asian Experience
S/r OOI Ee Ee, Malaysia
|
|
Q & A
|
|
|
|
Asian Network of Collaboration
( 1800 - 2200 )
|
|
|
TOP>
|
|
Main Programme, Day 4, 11 October 2008 (Saturday)
|
|
Suntec Singapore International Convention & Exhibition Centre
|
|
Room 1
|
Room
2
|
Room
4
|
|
11th International Conference on Thalassaemia &
Haemoglobinopathies
|
13th International TIF Conference for Thalassaemia Patients & Parents
|
|
Plenary 6
( 0800 - 0835 )
The Future of Stem Cell Transplant in Thalassaemia
Prof Guido LUCARELLI, Italy
|
|
|
Symposium 12
( 0835 - 1000 )
Haematopoietic Stem Cell Transplantation
Chairpersons: Prof Guido
LUCARELLI, Italy /
Dr William HWANG, Singapore
|
- Stem Cell Transplant for Thalassaemia - Who Should Have It?
Prof Guido LUCARELLI, Italy
- Stem Cell Transplant for Thalassaemia - Experience in a
Developing Country
Prof LIN Hai Peng, Malaysia
- Cord Blood Banking and Transplant in Thalassaemia
Dr William HWANG, Singapore
|
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1000 - 1020 )
|
Symposium 13 ( 1020 - 1200 )
Psychosocial Care
Chairpersons: Dr Michael
ANGASTINIOTIS, Cyprus /
Dr CHAN Mei Yoke, Singapore
|
- Improving the Quality of Life in Thalassaemia
Prof Antonio PIGA, Italy
- The Adolescent Thalassaemic
Dr Michael ANGASTINIOTIS, Cyprus
- Strategies to Ensure Compliance to Treatment in Thalassaemia
Dr Caterina BORGNA-PIGNATTI, Italy
- Patients' Perspective
Mr George CONSTANTINOU, United Kingdom
|
|
|
2nd Ithanet Scientific Workshop
(1030 - 1250)
|
|
Lunch Break
(
1200 - 1315)
|
Lunch Break
(1250 - 1400)
|
Symposium 14
( 1315 - 1455 )
Organisation of Thalassaemia Services
Chairperson/s: Prof Alan COHEN, United States of America /
Prof Antonio PIGA, Italy
|
- Organisation of Thalassaemia Services: The Sardinian
Experience
Prof Renzo GALANELLO, Italy
- Thalassaemia Services in Asia: The Asian Thalassaemia
Network
Dr Suthat FUCHAROEN, Thailand
- The Role of TIF and Patient Associations in Promoting the
Quality of Thalassaemia Services
Mr Panos ENGLEZOS, Cyprus
- Patients' Rights
Dr Androulla ELEFTHERIOU, Cyprus
- Introduction to M.Sc Course in Haemoglobinopathies
Dr Rekha BAJORIA, United Kingdom
|
|
2nd Ithanet Scientific Workshop
(1400 - 1500)
|
|
Tea break at Exhibition Area (Concourse, Level 3)
( 1455 - 1515 )
|
Symposium 15
( 1515 - 1600 )
Alpha Thalassaemia
Chairperson/s: Dr LAW Hai Yang, Singapore /
Prof Swee Lay THEIN, United Kingdom
|
- HbH Disease: A Wide Spectrum of Clinical Severity
Dr Vip VIPRAKASIT, Thailand
- Spectrum of Alpha Thalassaemia Mutations in SE Asia
Dr LAW Hai Yang, Singapore
- Understanding
Alpha-globin Gene Regulation
Dr Richard GIBBONS, United Kingdom
|
|
Parents'
Interactive Session
(1515 - 1630)
|
|
Symposium 16
( 1600
- 1700 )
Sickle Cell Disease
Chairperson/s: Dr Anselm LEE, Singapore /
Dr Mark WALTERS, United States of America
|
- Pathophysiology of Sickle Cell Disease
Dr Paul TELFER, United Kingdom
- Prevention of Complications in Sickle Cell Disease
Dr Bernard DAVIS, United Kingdom
- Stem Cell Transplantation for Sickle Cell
Anaemia: Why, When
and How?
Dr Mark WALTERS, United States of America
|
|
National Association Interactive Sessions ?
Developed Countries & Developing Countries
( 1630 - 1730 )
|
|
|
TOP>
|
|
A Novartis-Sponsored Satellite
Lunch Symposium,
8 October 2008 (Wednesday)
|
|
The Role of Bisphosphonates in Increasing Bone Mineral Density in Patients with Thalassaemia-Induced Osteoporosis
|
|
1230 - 1235
|
Welcome and Introduction
|
Ersi Voskaridou
|
|
1235 - 1255
|
Osteoporosis in Thalassaemia Patients
-
Prevalence of osteoporosis in patients with
thalassaemia and contributing factors (eg,
hypogonadism, bone marrow expansion)
-
Dysregulation of bone metabolism activation
of bone resorption in patients with thalassaemia
-
Zoledronic acid for treatment of thalassaemia
-induced osteoporosis dosing regimens
and results
|
Ersi Voskaridou
|
|
1255 - 1315
|
The Role of Bone Markers in Thalassaemia A Haematologic Perspective
-
Bone markers as measures of ongoing bone metabolism and response to therapy
-
Zoledronic acid in patients with thalassaemia
effect on bone markers and correlation
with improved skeletal health
|
Evangelos Terpos
|
|
1315 - 1325
|
Questions and Answers
|
Ersi Voskaridou
Evangelos Terpos
|
|
1325 - 1330
|
Concluding Remarks and Adjournment
|
Ersi Voskaridou
|
|
|
TOP>
|
|
A Novartis-Sponsored Satellite
Dinner Symposium,
8 October 2008 (Wednesday)
|
Optimizing Iron Chelation Therapy:
Bridging Clinical Data and Patient Management
|
|
1830 1930
|
Dinner
|
|
|
1930 1935
|
Welcome and introduction
|
John Porter (London, UK)
|
|
1935 2000
|
Complete iron chelation: progressing insights
Content
-
Iron overload and organ damage
-
Cardiac iron loading due to transfusional iron overload
-
NTBI and control with deferasirox
-
Removal of cardiac and hepatic iron with deferasirox
|
John Porter (London, UK)
|
|
2000 2025
|
Iron chelation therapy; what have we learned recently?
Content
-
Beneficial effects of iron chelation therapy
-
Short overview currently available iron chelators
-
TIF guidelines: iron chelation algorithm
-
Deferasirox
- 3.5 year clinical trial data on efficacy and safety
- new data on doses > 30 mg/kg/day
-
Effect of deferasirox on quality of life
|
Maria Domenica Cappellini (Milan, Italy)
|
|
2025 2050
|
How to optimally manage iron toxicity in our daily practice
Content
- Case study of a patient with thalassaemia
major who is treated effectively with deferasirox (dose > 30 mg/kg/day). The
case presentation will focus on:
- Tcorrect dosing (starting dose and titration) of deferasirox
- adverse event management
|
Ali Taher (Beirut, Lebanon)
|
|
2050 2100
|
Panel discussion
|
|
|
|
TOP>
|
|
Osato Research Institute
Lunch Symposium,
9 October 2008 (Thursday)
|
|
Protection of Oxidative Stress in Hemoglobinopathies and in DNA damaged liver cells by Fermented Papaya Preparation
(FPP)
|
Osato Research Institute is proud to host a Sponsored Lunch Symposium
on October 9th , 2008 at the International Thalassemia Conference
This free Lunch Symposium is being presented at
Ballroom 2 from 11H50 to 13H05
and its goal is to share with the medical professionals the clinical trials on:
Protection of Oxidative Stress in Hemoglobinopathies and in DNA damaged liver cells by Fermented Papaya Preparation
(FPP)
Introduction
Eliezer Rachmilewitz , MD
Edith Wolfson Medical Center, Holon-Israel
Speakers
What is Oxidative Stress?
Andrew Jenner, Ph.D.
National University of Singapore
The Effect of Fermented Papaya Preparation ( FPP ) on oxidative stress in hemoglobinopathies
Eitan Fibach, Ph.D.
( Hadassah University Hospital, Ein-Kerem, Jerusalem, Israel )
DNA Protection in the liver by FPP,
Evidence from clinical trials
Francisco Marotta , Ph.D.
University of Milano , Italy
Keep in mind that seating is limited to 500, so please come early to reserve your seat at the Lunch Symposium. We hope to see you there.
We encourage you to visit Osato International exhibiting booth # 6 during the conference to learn more about our product and the numerous independent scientific publications.
|
|
|
TOP>
|
|
* Programme subject to change without prior notice.
|
|
